Mosunetuzumab-axgb is a Bispecific T-cell Engager (BiTE) immunotherapy targeting CD3 on T-cells and CD20 on malignant B-cells.
The drug is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after several lines of therapy and approved under accelerated approval.